• Revenue: $2.7 billion, up 5% year-over-year.
• Products and Healthcare Services Revenue Growth: 5% overall, with nearly 6% growth in Medical Distribution.
• Patient Direct Revenue Growth: 6% year-over-year, driven by diabetes and sleep supplies.
• Gross Profit: $560 million, representing 20.6% of net revenue.
• Gross Margin: Expanded by 20 basis points from the second quarter of 2024.
• Distribution, Selling, and Administrative Expenses: $470 million, 17% of revenue.
• GAAP Operating Income: $24.2 million, slightly up from the previous year.
• Adjusted Operating Income: $84.2 million, flat year-over-year.
• Interest Expense: Just under $37 million, down $1.5 million from the previous year.
• GAAP Net Loss: $12.8 million or $0.17 per share.
• Adjusted Net Income: $33.1 million or $0.42 per share.
• Adjusted EBITDA: $142 million, up over 5% from the previous year.
• Operating Cash Flow: $27 million for the quarter.
• Debt Reduction: Nearly $200 million in the quarter, with over $0.75 billion paid down since the Apria acquisition.
• Full-Year Revenue Guidance: $10.6 billion to $10.8 billion.
• Full-Year Adjusted EBITDA Guidance: $540 million to $550 million.
• Full-Year Adjusted EPS Guidance: $1.45 to $1.55.

• Warning! GuruFocus has detected 3 Warning Sign with OMI.

Release Date: November 04, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Owens & Minor Inc (NYSE:OMI) achieved top-line growth across both segments, with exceptional demand for sleep supplies and diabetes products in the Patient Direct segment.
• The company reduced its total debt by nearly $200 million in the most recent quarter, bringing the total year-to-date debt reduction to approximately $210 million.
• The Products and Healthcare Services segment reported solid mid-single-digit revenue growth, driven by strengthening customer relationships and successful onboarding of new opportunities.
• Prices have stabilized in several key product categories, including gloves, indicating effective management of pricing strategies.
• Owens & Minor Inc (NYSE:OMI) is well-positioned to handle upcoming Chinese tariffs due to its manufacturing footprint and sourcing profile, which is not dependent on China.

Negative Points

• The North Carolina kitting operations faced disruptions due to hurricanes, causing delays in deliveries and impacting procedural volumes.
• The company continues to incur costs to manage around manufacturer supply chain problems stemming from hurricane-related infrastructure damage.
• Patient Direct segment faced a backlog of new patient starts due to delays in patient eligibility verification, which has been slow to resolve.
• Interest expenses remain high, with the third quarter interest expense just under $37 million, despite ongoing debt reduction efforts.
• The company faces potential headwinds from Chinese tariffs on key categories such as facial protection and gloves, which could impact the industry.

Q & A Highlights

Q: Can you discuss the impact of manufacturing supply chains, procedural volumes, and patient eligibility timing on your EBITDA guidance? A: Jonathan Leon, CFO: The unexpected driver was the cost incurred due to customers not getting what they need for procedural volumes, which made us reconsider our guidance. The backlog at Patient Direct has been improving and is expected to positively impact the fourth quarter. However, the larger impact is the cost and getting provider customers back online.

Q: How do you see the current challenges setting up for 2025, especially with the Rotech acquisition? A: Edward Pesicka, CEO: The investments in the sleep journey and revenue cycle will positively impact 2025. Procedural volumes should reset in January as deductibles renew. Tariffs on facial protection and gloves could impact the industry but may create opportunities for us due to our manufacturing footprint.

Q: Can you provide insights into the sustainability of Patient Direct's strong margin performance? A: Edward Pesicka, CEO: Margin expansion came from fixed cost leverage and gross margin improvements. Efforts to streamline onboarding and product renewal processes have been successful. We expect continued margin expansion year-over-year, with seasonal improvements in the back half of the year.

Q: What are the main factors contributing to the patient backlog, and why is it taking longer to resolve? A: Jonathan Leon, CFO: The backlog is primarily due to manual work required after losing some functionality from Change Healthcare. The delay is also due to incremental demand. We are working through the backlog while managing new patient starts.

Q: Are there any additional investments needed to take advantage of the upcoming tariffs with your current manufacturing footprint? A: Edward Pesicka, CEO: No additional capital investment is required. Our previous investments in glove manufacturing and facial protection facilities have positioned us well to handle the increased demand without further capital expenditure.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.